Literature DB >> 10752965

Visual field losses in subjects with migraine headaches.

A M McKendrick1, A J Vingrys, D R Badcock, J T Heywood.   

Abstract

PURPOSE: To characterize the visual fields of subjects with migraine headaches using static and temporal modulation perimetry.
METHODS: Sixteen subjects with migraines (15 with aura, 1 without) and 15 nonheadache controls were tested. Perimetry was conducted 7 days after the offset of a headache with both static and temporally modulated targets using the Medmont M-600 automated perimeter (Medmont Pty Ltd., Camberwell, Victoria, Australia). Flicker thresholds were measured using the autoflicker test, which varies flicker rate with eccentricity. A subset of four subjects with migraines (3 with aura, 1 without) had the temporal tuning characteristics of their loss evaluated using fixed temporal frequencies (4, 6, 9, 12, and 16 Hz).
RESULTS: Field losses were identified with temporal modulation perimetry in 11 of 16 migraine subjects. The majority of these losses occurred in the presence of normal static thresholds (8/11). The deficits displayed temporal tuning, being greatest for higher temporal frequencies (> or =9 Hz). None of the subjects revealed deficits typical of cortical lesions. The migraine-without-aura subject displayed a selective loss to temporally modulated stimuli, which was consistent with the aura group. This defect altered over time, decreasing for 30 to 40 days but remaining, to a smaller extent, for up to 75 days after the headache event.
CONCLUSIONS: Visual dysfunction that is selective for temporally modulated targets occurs in migraine subjects. The migrainous pattern of dysfunction shares some features with that identified in early stages of glaucoma and raises the possibility for a common precortical vascular involvement in these two conditions.

Entities:  

Mesh:

Year:  2000        PMID: 10752965

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  19 in total

1.  A comparison of perimetric results with the Medmont and Humphrey perimeters.

Authors:  J Landers; A Sharma; I Goldberg; S Graham
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

2.  Topical beta-blocker treatment for migraine.

Authors:  Patrick J T Chiam
Journal:  Int Ophthalmol       Date:  2012-01-26       Impact factor: 2.031

3.  Reduction in retinal nerve fiber layer thickness in migraine patients.

Authors:  Stefano Gipponi; Niccolò Scaroni; Elisabetta Venturelli; Eliana Forbice; Renata Rao; Paolo Liberini; Alessandro Padovani; Francesco Semeraro
Journal:  Neurol Sci       Date:  2012-04-26       Impact factor: 3.307

4.  [Importance of perimetric differential diagnostics in patients with primary open-angle glaucoma].

Authors:  C Erb; K Göbel
Journal:  Ophthalmologe       Date:  2013-02       Impact factor: 1.059

5.  Visual Field Losses in Patients with Migraine without Aura and Tension-Type Headache.

Authors:  Arif Ü Yener; Osman Korucu
Journal:  Neuroophthalmology       Date:  2017-01-11

Review 6.  Retinal migraine.

Authors:  Brian M Grosberg; Seymour Solomon; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2005-08

7.  Correlation of visual field defects and optical coherence tomography finding in migraine patients.

Authors:  Abdelrahman Gaber Salman; Mahmoud Ahmad Abdel Hamid; Dina Ezzat Mansour
Journal:  Saudi J Ophthalmol       Date:  2014-07-01

8.  Short-wavelength automated perimetry in patients with migraine.

Authors:  Ozlem Yenice; Ahmet Temel; Burçin Incili; Neşe Tuncer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-21       Impact factor: 3.117

Review 9.  Retinal nerve fiber layer changes in migraine: a systematic review and meta-analysis.

Authors:  HongJie Zhang; PanWen Zhao; PingLei Pan; XiaoGuang Lin; ZhongQuan Yi; XueLing Zhang; QinQin Liu; Hui Zhang; RuYuan Cai; ChaoChun Chen
Journal:  Neurol Sci       Date:  2021-01-13       Impact factor: 3.307

Review 10.  Perceptive aspects of visual aura.

Authors:  Carlo Aleci; William Liboni
Journal:  Neurol Sci       Date:  2009-09-25       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.